Improved deal means new treatment for a type of advanced breast cancer can be recommended by NICE
Draft guidance published by NICE recommends atezolizumab for treating people with a type of breast cancer, called triple negative breast cancer, that has spread to other parts of the body.
The positive recommendation follows consultation on NICE’s previous draft guidance which did not recommend atezolizumab. The company has agreed to provide a larger discount to the list price of the drug following a deal with NHS England & NHS Improvement.
Around 2000 people in England have triple negative breast cancer, of whom around 600 people would be eligible for treatment with atezolizumab and nab-paclitaxel.
Full detail at National Institute for Health & Care Excellence